Evidence map›Paper›PMID 38471504›Full record

ArticleCell reports. Medicine2024

An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI.

Alonso Garcia-Ruiz, Albert Pons-Escoda, Francesco Grussu, Pablo Naval-Baudin, Camilo Monreal-Aguero, Gretchen Hermann, Roshan Karunamuni, Marta Ligero, Antonio Lopez-Rueda, Laura Oleaga and 7 more

Abstract read
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alonso Garcia-RuizRadiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Albert Pons-EscodaRadiology Department, Bellvitge University Hospital, 08907 Barcelona, Spain; Neuro-Oncology Unit, Institut d'Investigacio Biomedica de Bellvitge (IDIBELL), 08907 Barcelona, Spain.
Francesco GrussuRadiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Pablo Naval-BaudinRadiology Department, Bellvitge University Hospital, 08907 Barcelona, Spain.
Camilo Monreal-AgueroRadiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Gretchen HermannRadiation Medicine Department and Applied Sciences, University of California, San Diego, La Jolla, CA 92093, USA.
Roshan KarunamuniRadiation Medicine Department and Applied Sciences, University of California, San Diego, La Jolla, CA 92093, USA.
Marta LigeroRadiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Antonio Lopez-RuedaRadiology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Laura OleagaRadiology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
M Álvaro BerbísRadiology Department, HT Medica, Hospital San Juan de Dios, 14012 Cordoba, Spain.
Alberto Cabrera-ZubizarretaRadiology Department, HT Medica, 23008 Jaen, Spain.
Teodoro Martin-NoguerolRadiology Department, HT Medica, 23008 Jaen, Spain.
Antonio LunaRadiology Department, HT Medica, 23008 Jaen, Spain.
Tyler M SeibertRadiation Medicine Department and Applied Sciences, University of California, San Diego, La Jolla, CA 92093, USA; Radiology Department, University of California, San Diego, La Jolla, CA 92093, USA; Bioengineering Department, University of California, San Diego, La Jolla, CA 92093, USA.
Carlos MajosRadiology Department, Bellvitge University Hospital, 08907 Barcelona, Spain; Neuro-Oncology Unit, Institut d'Investigacio Biomedica de Bellvitge (IDIBELL), 08907 Barcelona, Spain.
Raquel Perez-LopezRadiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain. Electronic address: rperez@vhio.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noninvasive differential diagnosis of brain tumors is currently based on the assessment of magnetic resonance imaging (MRI) coupled with dynamic susceptibility contrast (DSC). However, a definitive diagnosis often requires neurosurgical interventions that compromise patients' quality of life. We apply deep learning on DSC images from histology-confirmed patients with glioblastoma, metastasis, or lymphoma. The convolutional neural network trained on ∼50,000 voxels from 40 patients provides intratumor probability maps that yield clinical-grade diagnosis. Performance is tested in 400 additional cases and an external validation cohort of 128 patients. The tool reaches a three-way accuracy of 0.78, superior to the conventional MRI metrics cerebral blood volume (0.55) and percentage of signal recovery (0.59), showing high value as a support diagnostic tool. Our open-access software, Diagnosis In Susceptibility Contrast Enhancing Regions for Neuro-oncology (DISCERN), demonstrates its potential in aiding medical decisions for brain tumor diagnosis using standard-of-care MRI.

Indexed as

Brain NeoplasmsDeep LearningHumansMagnetic Resonance ImagingPerfusionQuality of Lifedeep learningdiagnosisdynamic susceptibility contrastglioblastomalymphomametastasisneuro-oncologyperfusion MRI

Identifiers

PMID38471504
PMCPMC10983037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.